FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082726774> ?p ?o ?g. }

• W2082726774 endingPage "1327" @default.
• W2082726774 startingPage "1317" @default.
• W2082726774 abstract "The majority of targeted personalized cancer therapies are effective only in part of the patients, and most of these drugs are excessively expensive. Therefore, methods are urgently required, which reveal already early during treatment, whether the therapy is effective. In the present report, monitoring of circulating epithelial tumor cells (CETC) was used as a timely control of trastuzumab therapy in patients with HER2/neu-positive breast cancer.Seventy-nine sequential HER2/neu-positive breast cancer patients, 35 without trastuzumab, and 36 treated with 1 year of trastuzumab treatment were included. CETC from unseparated white blood cells stained with FITC-anti-EpCAM were analyzed repeatedly during chemotherapy and between 2 and 10 times during 1 year of maintenance treatment or observation.Patients treated with trastuzumab had a better relapse-free survival than patients without trastuzumab treatment during the first 2-4 years of follow-up. Decrease in numbers or no change versus highly variable numbers or increase (fivefold or more) allowed to discriminate highly significantly and clearly (P < 0.0001, hazard ratio 5.5) between patients with a low or high risk of relapse. An increase in CETC was accompanied by an increasing portion of cells containing a very high number of HER2/neu gene amplificates.Analysis of the behavior of CETC can, in the future, contribute to evaluate the efficacy of targeted therapy early during the course of the disease, sparing patients unnecessary treatment but also to reduce the costs for the health system and to downsize the extent and length of clinical studies." @default.
• W2082726774 created "2016-06-24" @default.
• W2082726774 creator A5011116789 @default.
• W2082726774 creator A5027524393 @default.
• W2082726774 creator A5032366029 @default.
• W2082726774 creator A5059321249 @default.
• W2082726774 creator A5063234663 @default.
• W2082726774 creator A5077320747 @default.
• W2082726774 creator A5088939314 @default.
• W2082726774 date "2011-07-08" @default.
• W2082726774 modified "2023-10-16" @default.
• W2082726774 title "Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma" @default.
• W2082726774 cites W1979160606 @default.
• W2082726774 cites W2004391300 @default.
• W2082726774 cites W2017780448 @default.
• W2082726774 cites W2044865080 @default.
• W2082726774 cites W2051447115 @default.
• W2082726774 cites W2053848912 @default.
• W2082726774 cites W2056807656 @default.
• W2082726774 cites W2066973526 @default.
• W2082726774 cites W2095259408 @default.
• W2082726774 cites W2096634042 @default.
• W2082726774 cites W2096818458 @default.
• W2082726774 cites W2103353315 @default.
• W2082726774 cites W2111976640 @default.
• W2082726774 cites W2117305280 @default.
• W2082726774 cites W2118764768 @default.
• W2082726774 cites W2129530019 @default.
• W2082726774 cites W2129772273 @default.
• W2082726774 cites W2133105825 @default.
• W2082726774 cites W2136431957 @default.
• W2082726774 cites W2136603221 @default.
• W2082726774 cites W2137935868 @default.
• W2082726774 cites W2144124503 @default.
• W2082726774 cites W2146384083 @default.
• W2082726774 cites W2149908785 @default.
• W2082726774 cites W2153605921 @default.
• W2082726774 cites W2156909204 @default.
• W2082726774 cites W2276772166 @default.
• W2082726774 cites W2326993199 @default.
• W2082726774 doi "https://doi.org/10.1007/s00432-011-1000-6" @default.
• W2082726774 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3155034" @default.
• W2082726774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21739182" @default.
• W2082726774 hasPublicationYear "2011" @default.
• W2082726774 type Work @default.
• W2082726774 sameAs 2082726774 @default.
• W2082726774 citedByCount "31" @default.
• W2082726774 countsByYear W20827267742012 @default.
• W2082726774 countsByYear W20827267742013 @default.
• W2082726774 countsByYear W20827267742014 @default.
• W2082726774 countsByYear W20827267742015 @default.
• W2082726774 countsByYear W20827267742016 @default.
• W2082726774 countsByYear W20827267742017 @default.
• W2082726774 countsByYear W20827267742018 @default.
• W2082726774 countsByYear W20827267742019 @default.
• W2082726774 countsByYear W20827267742020 @default.
• W2082726774 countsByYear W20827267742021 @default.
• W2082726774 crossrefType "journal-article" @default.
• W2082726774 hasAuthorship W2082726774A5011116789 @default.
• W2082726774 hasAuthorship W2082726774A5027524393 @default.
• W2082726774 hasAuthorship W2082726774A5032366029 @default.
• W2082726774 hasAuthorship W2082726774A5059321249 @default.
• W2082726774 hasAuthorship W2082726774A5063234663 @default.
• W2082726774 hasAuthorship W2082726774A5077320747 @default.
• W2082726774 hasAuthorship W2082726774A5088939314 @default.
• W2082726774 hasBestOaLocation W20827267741 @default.
• W2082726774 hasConcept C121608353 @default.
• W2082726774 hasConcept C126322002 @default.
• W2082726774 hasConcept C143998085 @default.
• W2082726774 hasConcept C194409129 @default.
• W2082726774 hasConcept C2776694085 @default.
• W2082726774 hasConcept C2776872082 @default.
• W2082726774 hasConcept C2777329042 @default.
• W2082726774 hasConcept C2779013556 @default.
• W2082726774 hasConcept C2779529041 @default.
• W2082726774 hasConcept C2779786085 @default.
• W2082726774 hasConcept C2781230642 @default.
• W2082726774 hasConcept C3018521938 @default.
• W2082726774 hasConcept C530470458 @default.
• W2082726774 hasConcept C61238886 @default.
• W2082726774 hasConcept C71924100 @default.
• W2082726774 hasConceptScore W2082726774C121608353 @default.
• W2082726774 hasConceptScore W2082726774C126322002 @default.
• W2082726774 hasConceptScore W2082726774C143998085 @default.
• W2082726774 hasConceptScore W2082726774C194409129 @default.
• W2082726774 hasConceptScore W2082726774C2776694085 @default.
• W2082726774 hasConceptScore W2082726774C2776872082 @default.
• W2082726774 hasConceptScore W2082726774C2777329042 @default.
• W2082726774 hasConceptScore W2082726774C2779013556 @default.
• W2082726774 hasConceptScore W2082726774C2779529041 @default.
• W2082726774 hasConceptScore W2082726774C2779786085 @default.
• W2082726774 hasConceptScore W2082726774C2781230642 @default.
• W2082726774 hasConceptScore W2082726774C3018521938 @default.
• W2082726774 hasConceptScore W2082726774C530470458 @default.
• W2082726774 hasConceptScore W2082726774C61238886 @default.
• W2082726774 hasConceptScore W2082726774C71924100 @default.
• W2082726774 hasIssue "9" @default.
• W2082726774 hasLocation W20827267741 @default.

• next